Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Atara Biotherapeutics stock

Learn how to easily invest in Atara Biotherapeutics stock.

Atara Biotherapeutics is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 340 staff and has a trailing 12-month revenue of around $70.9 million.

How to buy Atara Biotherapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – ATRA. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Atara Biotherapeutics stock price (NASDAQ: ATRA)

Use our graph to track the performance of ATRA stocks over time.

Atara Biotherapeutics shares at a glance

Information last updated 2023-01-26.
Latest market close$4.94
52-week range$2.83 - $16.07
50-day moving average $3.98
200-day moving average $4.84
Wall St. target price$18.88
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.65

Buy Atara Biotherapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Atara Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atara Biotherapeutics price performance over time

Historical closes compared with the close of $4.94 from 2023-01-26

1 week (2023-01-20) 26.99%
1 month (2022-12-28) 65.22%
3 months (2022-10-28) 2.28%
6 months (2022-07-28) 55.35%
1 year (2022-01-28) -66.76%
2 years (2021-01-28) -74.00%
3 years (2020-01-28) 14
5 years (2018-01-26) 37.25

Atara Biotherapeutics financials

Revenue TTM $70.9 million
Gross profit TTM $-229,598,000
Return on assets TTM -45.58%
Return on equity TTM -99.38%
Profit margin 0%
Book value $1.97
Market capitalisation $451.1 million

TTM: trailing 12 months

Atara Biotherapeutics share dividends

We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.

Atara Biotherapeutics share price volatility

Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $2.83 up to $16.07. A popular way to gauge a stock's volatility is its "beta".

ATRA.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 0.7677. This would suggest that Atara Biotherapeutics's shares are less volatile than average (for this exchange).

Atara Biotherapeutics overview

Atara Biotherapeutics, Inc. , an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.

Frequently asked questions

What percentage of Atara Biotherapeutics is owned by insiders or institutions?
Currently 0.796% of Atara Biotherapeutics shares are held by insiders and 107.731% by institutions.
How many people work for Atara Biotherapeutics?
Latest data suggests 340 work at Atara Biotherapeutics.
When does the fiscal year end for Atara Biotherapeutics?
Atara Biotherapeutics's fiscal year ends in December.
Where is Atara Biotherapeutics based?
Atara Biotherapeutics's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
What is Atara Biotherapeutics's ISIN number?
Atara Biotherapeutics's international securities identification number is: US0465131078
What is Atara Biotherapeutics's CUSIP number?
Atara Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 046513107

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site